Hypofractionated radiotherapy combined with bevacizumab plus low-dose ifosfamide, carboplatin, and etoposide as second-line chemoradiotherapy for progressing spinal diffuse midline glioma, H3K27-altered: illustrative case.

MLA

Nakayasu, Shintaro, et al. “Hypofractionated Radiotherapy Combined with Bevacizumab plus Low-Dose Ifosfamide, Carboplatin, and Etoposide as Second-Line Chemoradiotherapy for Progressing Spinal Diffuse Midline Glioma, H3K27-Altered: Illustrative Case.” Journal of Neurosurgery. Case Lessons, vol. 8, no. 7, Aug. 2024. EBSCOhost, https://doi.org/10.3171/CASE2464.

APA

Nakayasu, S., Tanji, M., Uto, M., Takeuchi, Y., Makino, Y., Yamamoto Hattori, E., Terada, Y., Sano, N., Mineharu, Y., Mizowaki, T., & Arakawa, Y. (2024). Hypofractionated radiotherapy combined with bevacizumab plus low-dose ifosfamide, carboplatin, and etoposide as second-line chemoradiotherapy for progressing spinal diffuse midline glioma, H3K27-altered: illustrative case. Journal of Neurosurgery. Case Lessons, 8(7). https://doi.org/10.3171/CASE2464

Chicago

Nakayasu, Shintaro, Masahiro Tanji, Megumi Uto, Yasuhide Takeuchi, Yasuhide Makino, Etsuko Yamamoto Hattori, Yukinori Terada, et al. 2024. “Hypofractionated Radiotherapy Combined with Bevacizumab plus Low-Dose Ifosfamide, Carboplatin, and Etoposide as Second-Line Chemoradiotherapy for Progressing Spinal Diffuse Midline Glioma, H3K27-Altered: Illustrative Case.” Journal of Neurosurgery. Case Lessons 8 (7). doi:10.3171/CASE2464.